:线

Roberto Mina1, Silvia Mangiacavalli2, Bernardo Rossini3

  • 1Division of Hematology, AOU Città della Salute e della Scienza di Torino, and the Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.

概括

由于新疗法,接受一线治疗的多发性骨髓瘤患者数量正在增加. 然而,这导致后期治疗线路中耐药患者的显著增加,突出显示了对新型治疗的需求.